CN101057862A - 一种防治老年性骨关节病的药物组合物 - Google Patents
一种防治老年性骨关节病的药物组合物 Download PDFInfo
- Publication number
- CN101057862A CN101057862A CN 200710105249 CN200710105249A CN101057862A CN 101057862 A CN101057862 A CN 101057862A CN 200710105249 CN200710105249 CN 200710105249 CN 200710105249 A CN200710105249 A CN 200710105249A CN 101057862 A CN101057862 A CN 101057862A
- Authority
- CN
- China
- Prior art keywords
- calcium
- hydrogen phosphate
- pharmaceutical composition
- calcium hydrogen
- chondroitin sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 26
- 206010057178 Osteoarthropathies Diseases 0.000 title 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims abstract description 70
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 57
- 239000011575 calcium Substances 0.000 claims abstract description 54
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 54
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 52
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 52
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 52
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 68
- 229960005069 calcium Drugs 0.000 claims description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 46
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 claims description 43
- 229960001911 glucosamine hydrochloride Drugs 0.000 claims description 43
- 201000008482 osteoarthritis Diseases 0.000 claims description 34
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 19
- 239000000741 silica gel Substances 0.000 claims description 19
- 229910002027 silica gel Inorganic materials 0.000 claims description 19
- 239000003826 tablet Substances 0.000 claims description 17
- 235000019359 magnesium stearate Nutrition 0.000 claims description 13
- 239000000314 lubricant Substances 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 8
- 239000007910 chewable tablet Substances 0.000 claims description 8
- 229940068682 chewable tablet Drugs 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 7
- 238000004132 cross linking Methods 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 7
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 6
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 239000002270 dispersing agent Substances 0.000 claims description 4
- -1 hydroxypropyl Chemical group 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 14
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract description 9
- 239000011574 phosphorus Substances 0.000 abstract description 9
- 229910052698 phosphorus Inorganic materials 0.000 abstract description 9
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 3
- CHVZQMAANSUXJU-JJKGCWMISA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide;hydrochloride Chemical compound Cl.NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO CHVZQMAANSUXJU-JJKGCWMISA-N 0.000 abstract 2
- 230000035563 calcemia Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 35
- 239000008187 granular material Substances 0.000 description 20
- 210000000988 bone and bone Anatomy 0.000 description 16
- 239000011248 coating agent Substances 0.000 description 15
- 238000000576 coating method Methods 0.000 description 15
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 14
- 210000000845 cartilage Anatomy 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 8
- 239000004227 calcium gluconate Substances 0.000 description 8
- 229960004494 calcium gluconate Drugs 0.000 description 8
- 235000013927 calcium gluconate Nutrition 0.000 description 8
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 8
- 239000001527 calcium lactate Substances 0.000 description 8
- 229960002401 calcium lactate Drugs 0.000 description 8
- 235000011086 calcium lactate Nutrition 0.000 description 8
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical group [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 8
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 7
- 206010003246 arthritis Diseases 0.000 description 7
- 238000005728 strengthening Methods 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 210000001188 articular cartilage Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000037182 bone density Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 235000011194 food seasoning agent Nutrition 0.000 description 4
- 229960002442 glucosamine Drugs 0.000 description 4
- 239000001117 sulphuric acid Substances 0.000 description 4
- 235000011149 sulphuric acid Nutrition 0.000 description 4
- 206010006966 Calcium intoxication Diseases 0.000 description 3
- 208000037147 Hypercalcaemia Diseases 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 229960003563 calcium carbonate Drugs 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007919 dispersible tablet Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229960002849 glucosamine sulfate Drugs 0.000 description 3
- 230000000148 hypercalcaemia Effects 0.000 description 3
- 208000030915 hypercalcemia disease Diseases 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 108090001069 Chymopapain Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ISWQCIVKKSOKNN-UHFFFAOYSA-L Tiron Chemical compound [Na+].[Na+].OC1=CC(S([O-])(=O)=O)=CC(S([O-])(=O)=O)=C1O ISWQCIVKKSOKNN-UHFFFAOYSA-L 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 229960002976 chymopapain Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 2
- 229960005293 etodolac Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000007952 growth promoter Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108010048734 sclerotin Proteins 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- FGNPLIQZJCYWLE-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;sulfuric acid Chemical compound OS(O)(=O)=O.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO FGNPLIQZJCYWLE-BTVCFUMJSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010005963 Bone formation increased Diseases 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 206010007733 Catabolic state Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010020674 Hypermetabolism Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- FGAGEDGBNKPEMD-NSEZLWDYSA-N [K].OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO Chemical compound [K].OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO FGAGEDGBNKPEMD-NSEZLWDYSA-N 0.000 description 1
- IOVFHCCDMUAUPM-NSEZLWDYSA-N [Na].OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO Chemical compound [Na].OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO IOVFHCCDMUAUPM-NSEZLWDYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- FGAMKHCTXLHFAL-FRWAFGSFSA-L dipotassium (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol sulfate Chemical group [K+].[K+].[O-]S([O-])(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O FGAMKHCTXLHFAL-FRWAFGSFSA-L 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940076049 glucosamine hydrochloride 375 mg Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940084936 gonak Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710105249A CN100596278C (zh) | 2007-05-24 | 2007-05-24 | 一种防治老年性骨关节病的药物组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710105249A CN100596278C (zh) | 2007-05-24 | 2007-05-24 | 一种防治老年性骨关节病的药物组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101057862A true CN101057862A (zh) | 2007-10-24 |
| CN100596278C CN100596278C (zh) | 2010-03-31 |
Family
ID=38864265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710105249A Expired - Fee Related CN100596278C (zh) | 2007-05-24 | 2007-05-24 | 一种防治老年性骨关节病的药物组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100596278C (zh) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101904866A (zh) * | 2010-09-07 | 2010-12-08 | 许阳 | 一种治疗骨质疏松的药物组合物及其制备方法 |
| CN101690728B (zh) * | 2009-09-23 | 2011-09-21 | 沈阳亿灵医药科技有限公司 | 一种治疗骨性关节炎的组合物 |
| CN102342954A (zh) * | 2010-08-04 | 2012-02-08 | 张义兴 | 一种用于改善骨关节炎的口服液体组合物及其制备方法 |
| CN102423035A (zh) * | 2011-11-25 | 2012-04-25 | 苏州先阔生物科技有限公司 | 一种用于辅助治疗中老年退行性骨关节疾病的含低聚木糖的保健食品 |
| CN101647805B (zh) * | 2009-09-04 | 2012-07-18 | 江苏江山制药有限公司 | 用于缓解和预防骨关节炎的氨基葡萄糖咀嚼片及制备方法 |
| CN102626225A (zh) * | 2012-04-25 | 2012-08-08 | 广东仙乐制药有限公司 | 一种具有增加骨密度和保护关节功能的保健食品及其制备方法 |
| CN104873534A (zh) * | 2015-04-03 | 2015-09-02 | 广东先强药业有限公司 | 一种氨基葡萄糖软骨素片及其制备工艺 |
| WO2021179319A1 (zh) * | 2020-03-13 | 2021-09-16 | 南京汉欣医药科技有限公司 | 一种含水解硫酸软骨素的用于防治骨关节病的组合物 |
| CN114288349A (zh) * | 2022-01-05 | 2022-04-08 | 盖茨汉普(武汉)植物应用研究有限公司 | 一种MitoQ氨糖软胶囊制剂配方及制备工艺 |
| US11572421B2 (en) | 2019-11-01 | 2023-02-07 | Nanjing Hanxin Pharmaceutical Technology Co., Ltd. | Low molecular weight chondroitin sulfate, composition, preparation method and use thereof |
-
2007
- 2007-05-24 CN CN200710105249A patent/CN100596278C/zh not_active Expired - Fee Related
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101647805B (zh) * | 2009-09-04 | 2012-07-18 | 江苏江山制药有限公司 | 用于缓解和预防骨关节炎的氨基葡萄糖咀嚼片及制备方法 |
| CN101690728B (zh) * | 2009-09-23 | 2011-09-21 | 沈阳亿灵医药科技有限公司 | 一种治疗骨性关节炎的组合物 |
| CN102342954A (zh) * | 2010-08-04 | 2012-02-08 | 张义兴 | 一种用于改善骨关节炎的口服液体组合物及其制备方法 |
| CN102342954B (zh) * | 2010-08-04 | 2013-05-01 | 张义兴 | 一种用于改善骨关节炎的口服液体组合物及其制备方法 |
| CN101904866A (zh) * | 2010-09-07 | 2010-12-08 | 许阳 | 一种治疗骨质疏松的药物组合物及其制备方法 |
| CN102423035A (zh) * | 2011-11-25 | 2012-04-25 | 苏州先阔生物科技有限公司 | 一种用于辅助治疗中老年退行性骨关节疾病的含低聚木糖的保健食品 |
| CN102626225A (zh) * | 2012-04-25 | 2012-08-08 | 广东仙乐制药有限公司 | 一种具有增加骨密度和保护关节功能的保健食品及其制备方法 |
| CN104873534A (zh) * | 2015-04-03 | 2015-09-02 | 广东先强药业有限公司 | 一种氨基葡萄糖软骨素片及其制备工艺 |
| US11572421B2 (en) | 2019-11-01 | 2023-02-07 | Nanjing Hanxin Pharmaceutical Technology Co., Ltd. | Low molecular weight chondroitin sulfate, composition, preparation method and use thereof |
| WO2021179319A1 (zh) * | 2020-03-13 | 2021-09-16 | 南京汉欣医药科技有限公司 | 一种含水解硫酸软骨素的用于防治骨关节病的组合物 |
| CN114288349A (zh) * | 2022-01-05 | 2022-04-08 | 盖茨汉普(武汉)植物应用研究有限公司 | 一种MitoQ氨糖软胶囊制剂配方及制备工艺 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100596278C (zh) | 2010-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101057862A (zh) | 一种防治老年性骨关节病的药物组合物 | |
| AU747595B2 (en) | Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and S-adenosylmethionine | |
| CN101559218B (zh) | 一种具有增加骨密度功能的组合物 | |
| CN106213492A (zh) | 一种提升运动机能并增加骨密度的健康产品及制备方法 | |
| CN1162096C (zh) | 柠檬酸钙钾组合物和生产方法 | |
| AU2013252435B2 (en) | Dietary fiber compositions for the treatment of metabolic disease | |
| CN1681485A (zh) | 莫达非尼的新药物剂型 | |
| JP5689458B2 (ja) | グルコサミンを包含する栄養補助食品を安定化させる方法 | |
| CN1954814A (zh) | 一种具有协同作用治疗痛风的药物组合物及其制备方法 | |
| CN1250227C (zh) | 盐酸氨基葡萄糖药物组合物 | |
| US7214666B1 (en) | Composition of orally administered nutritional supplements to repair articular cartilage | |
| CN1823764A (zh) | 一种含有雷奈酸锶和维生素d药物组合物 | |
| CN1316978C (zh) | 复方硫酸氨基葡萄糖分散片制剂及其制备方法 | |
| US20130065823A1 (en) | Supplement for Strengthening the Muscles of a Human | |
| CN104523804B (zh) | 一种增加骨密度的胶囊及其制备方法 | |
| CN101066252A (zh) | 氨基葡萄糖钙片制剂及其制备方法 | |
| CN1621044A (zh) | 一种预防和治疗关节炎的组合物、含有该组合物制剂及其制备工艺和用途 | |
| CN1823808A (zh) | 盐酸克林霉素棕榈酸酯分散片及其制备方法 | |
| CN1626108A (zh) | 阿卡波糖肠溶片及制备方法 | |
| CN1231175A (zh) | 氟酰褪黑素及其组合物和制剂 | |
| CN1781486A (zh) | 一种复方氨基酸与维生素胶囊制剂及其制备方法 | |
| CN1679941A (zh) | 一种由牛磺酸和治疗肝病的药物组成的复方制剂及其制备方法 | |
| CN1907269A (zh) | 氨基葡萄糖复合泡腾制剂 | |
| CN1268327C (zh) | 布洛芬精氨酸伪麻黄碱复方制剂 | |
| CN1709502A (zh) | 一种复合型关节改善口服液 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: WUHU SINOCAN BIO-PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHANG YIXING Effective date: 20101227 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200031 ROOM 106, BUILDING 5, BIYU GARDEN, ERLI STREET, HEFEI CITY, ANHUI PROVINCE TO: 241003 NEW AND HIGH TECHNOLOGY INDUSTRIAL DEVELOPMENT AREA, WUHU CITY, ANHUI PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20101227 Address after: 241003 hi tech Industrial Development Zone, Anhui, Wuhu Patentee after: Biological Pharmaceutical Co., Ltd. Wuhu Zhongjia Address before: 200031 Anhui city of Hefei Province in the two Street Garden Building 5, room 106, Bi rain Patentee before: Zhang Yixing |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100331 Termination date: 20150524 |
|
| EXPY | Termination of patent right or utility model |